Optimization of Smoking Cessation Strategies Concurrent With Treatment of Tobacco Related Malignancies

NCT ID: NCT02048917

Last Updated: 2020-01-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

93 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-07-22

Study Completion Date

2019-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to find an optimal smoking cessation strategy in patients undergoing therapy for lung and head and neck cancers at selected cancer centers in Kentucky by delivering high quality smoking cessation to all enrolled patients. This study will also examine the feasibility of routinely implementing an array of smoking cessation strategies for this patient population.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects enrolled in the study will be placed in one of twelve treatment arms. Subjects in each of the twelve treatment regimens will receive either varenicline or bupropion or long-acting nicotine replacement therapy, with or without use of supplemental nicotine replacement therapy, and in combination with either standard of care smoking cessation counseling or high intensity/motivational smoking cessation counseling.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer Head and Neck Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

High Intensity Counseling + Long Acting NRT + PRN NRT

High Intensity Counseling + Long Acting NRT + PRN NRT

Group Type EXPERIMENTAL

High Intensity Counseling + Long Acting NRT + PRN NRT

Intervention Type DRUG

High Intensity Counseling + Long Acting NRT + PRN NRT

High Intensity Counseling + bupropion + PRN NRT

High Intensity Counseling + bupropion + PRN NRT

Group Type EXPERIMENTAL

High Intensity Counseling + bupropion + PRN NRT

Intervention Type DRUG

High Intensity Counseling + bupropion + PRN NRT

High Intensity Counseling + varenicline + PRN NRT

High Intensity Counseling + varenicline + PRN NRT

Group Type EXPERIMENTAL

High Intensity Counseling + varenicline + PRN NRT

Intervention Type DRUG

High Intensity Counseling + varenicline + PRN NRT

High Intensity Counseling + Long Acting NRT

High Intensity Counseling + Long Acting NRT

Group Type EXPERIMENTAL

High Intensity Counseling + Long Acting NRT

Intervention Type DRUG

High Intensity Counseling + Long Acting NRT

High Intensity Counseling + bupropion

High Intensity Counseling + bupropion

Group Type EXPERIMENTAL

High Intensity Counseling + bupropion

Intervention Type DRUG

High Intensity Counseling + bupropion

High Intensity Counseling + varenicline

High Intensity Counseling + varenicline

Group Type EXPERIMENTAL

High Intensity Counseling + varenicline

Intervention Type DRUG

High Intensity Counseling + varenicline

Low Intensity Counseling + Long Acting NRT + PRN NRT

Low Intensity Counseling + Long Acting NRT + PRN NRT

Group Type EXPERIMENTAL

Low Intensity Counseling + Long Acting NRT + PRN NRT

Intervention Type DRUG

Low Intensity Counseling + Long Acting NRT + PRN NRT

Low Intensity Counseling + bupropion + PRN NRT

Low Intensity Counseling + bupropion + PRN NRT

Group Type EXPERIMENTAL

Low Intensity Counseling + bupropion + PRN NRT

Intervention Type DRUG

Low Intensity Counseling + bupropion + PRN NRT

Low Intensity Counseling + varenicline + PRN NRT

Low Intensity Counseling + varenicline + PRN NRT

Group Type EXPERIMENTAL

Low Intensity Counseling + varenicline + PRN NRT

Intervention Type DRUG

Low Intensity Counseling + varenicline + PRN NRT

Low Intensity Counseling + Long Acting NRT

Low Intensity Counseling + Long Acting NRT

Group Type EXPERIMENTAL

Low Intensity Counseling + Long Acting NRT

Intervention Type DRUG

Low Intensity Counseling + Long Acting NRT

Low Intensity Counseling + bupropion

Low Intensity Counseling + bupropion

Group Type EXPERIMENTAL

Low Intensity Counseling + bupropion

Intervention Type DRUG

Low Intensity Counseling + bupropion

Low Intensity Counseling + varenicline

Low Intensity Counseling + varenicline

Group Type EXPERIMENTAL

Low Intensity Counseling + varenicline

Intervention Type DRUG

Low Intensity Counseling + varenicline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

High Intensity Counseling + Long Acting NRT + PRN NRT

High Intensity Counseling + Long Acting NRT + PRN NRT

Intervention Type DRUG

High Intensity Counseling + bupropion + PRN NRT

High Intensity Counseling + bupropion + PRN NRT

Intervention Type DRUG

High Intensity Counseling + varenicline + PRN NRT

High Intensity Counseling + varenicline + PRN NRT

Intervention Type DRUG

High Intensity Counseling + Long Acting NRT

High Intensity Counseling + Long Acting NRT

Intervention Type DRUG

High Intensity Counseling + bupropion

High Intensity Counseling + bupropion

Intervention Type DRUG

High Intensity Counseling + varenicline

High Intensity Counseling + varenicline

Intervention Type DRUG

Low Intensity Counseling + Long Acting NRT + PRN NRT

Low Intensity Counseling + Long Acting NRT + PRN NRT

Intervention Type DRUG

Low Intensity Counseling + bupropion + PRN NRT

Low Intensity Counseling + bupropion + PRN NRT

Intervention Type DRUG

Low Intensity Counseling + varenicline + PRN NRT

Low Intensity Counseling + varenicline + PRN NRT

Intervention Type DRUG

Low Intensity Counseling + Long Acting NRT

Low Intensity Counseling + Long Acting NRT

Intervention Type DRUG

Low Intensity Counseling + bupropion

Low Intensity Counseling + bupropion

Intervention Type DRUG

Low Intensity Counseling + varenicline

Low Intensity Counseling + varenicline

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must be ≥ 18 years of age.
* Patient with newly diagnosed or recurrent, histologic diagnosis of any of the following tobacco related malignancies:

1. Lung or Bronchus cancer or Head \& Neck, cancers (all sites).
2. Esophagus, Stomach, Pancreas, Kidney, Urinary Bladder, Colon, Rectum, Cervix, Vulvar, Vaginal
3. Carcinoma in situ undergoing definitive surgical resection or treatment (ex: radiation of the larynx, and gynecologic tract hysterectomy, vulvectomy - except gynecologic patients undergoing ablative or local excisional therapies \[laser ablation,cervical conization, LEEP\].
* Having smoked at least 1 cigarette within 4 weeks of study enrollment.
* Having at least a 10-pack year history of cigarette smoking.
* Having smoked at least one cigarette within 1 month of cancer diagnosis.
* Life expectancy is greater than 1 year.
* Patient has an AUDIT score of \< 10.
* Patient has ECOG Performance Status of \<=2.
* Patients must have the ability to understand and the willingness to provide signed written informed consent document.

Exclusion Criteria

* Known allergy attributed to bupropion, varenicline, transdermal or lozenge nicotine.
* History of suicide attempt or preparation for attempt within the past 10 years.
* C-SRSS Baseline/Screening:

1. Patient response of "Yes" to any question except question 1.
2. Patient response of "Yes" to any question in column one (lifetime), except question 1, is not exclusionary unless judged by the investigator to be significant in ideation, intensity, behavior or attempts, and precludes participation.
* Hospitalized for psychiatric illness within the past two years.
* History of Bipolar disorder.
* Currently taking Bupropion for depression.
* Patient has taken monoamine oxidase inhibitors (MAOI) in the past two weeks.
* History of eating disorder such as anorexia or bulimia.
* Active widespread skin disorders such as psoriasis, chronic urticarial or dermatitis
* History of epilepsy or seizure disorder.
* Active severe kidney or liver disease.
* Women must not be pregnant or lactating. Women of reproductive-potential must have negative serum or urine pregnancy test within 7 days prior to study enrollment and agree to use method of contraception during and for 30 days following last cessation drug dose.
* Patients within three months of a myocardial infarction.
* Patients with unstable angina or serious arrhythmia.
* Patients with psychiatric disability judged by the investigator to be clinically significant so as to preclude informed consent or compliance with drug intake.
* Patient taking varenicline or bupropion within one month of study enrollment.
* Participation in any other investigational drug study within 4 weeks of study enrollment.
* Currently enrolled in other professional tobacco cessation therapeutic intervention.
* Enrollment in a concurrent cancer therapeutic trial will require prior review and approval by the study site PI to determine that there are no drug interactions concerns.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kentucky Lung Cancer Research Program

OTHER

Sponsor Role collaborator

University of Kentucky

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Joseph Valentino

Study Chair

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joseph Valentino, M.D.

Role: PRINCIPAL_INVESTIGATOR

University of Kentucky

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

King's Daughters Medical Center

Ashland, Kentucky, United States

Site Status

Hardin Memorial Health Cancer Care Center

Elizabethtown, Kentucky, United States

Site Status

ARH Cancer Center

Hazard, Kentucky, United States

Site Status

Kentucky Cancer Clinic

Hazard, Kentucky, United States

Site Status

Lexington Veterans Affair Medical Center

Lexington, Kentucky, United States

Site Status

University Of Kentucky, Markey Cancer Center

Lexington, Kentucky, United States

Site Status

University of Louisville, James Graham Brown Cancer Center

Louisville, Kentucky, United States

Site Status

St. Claire Regional Medical Center

Morehead, Kentucky, United States

Site Status

Owensboro Health

Owensboro, Kentucky, United States

Site Status

St. Mary's Medical Center

Huntington, West Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Livingstone-Banks J, Fanshawe TR, Thomas KH, Theodoulou A, Hajizadeh A, Hartman L, Lindson N. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2023 May 5;5(5):CD006103. doi: 10.1002/14651858.CD006103.pub8.

Reference Type DERIVED
PMID: 37142273 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KCTN-1301

Identifier Type: OTHER

Identifier Source: secondary_id

MCC-13-MULTI-13-KCTN-1301

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Tobacco Use Treatment in Cancer Patients
NCT03482583 COMPLETED PHASE4
Disease Management for Smoking Cessation
NCT00440115 COMPLETED PHASE3
Smoking Cessation Treatment for Head & Neck Cancer Patients
NCT01098955 ACTIVE_NOT_RECRUITING EARLY_PHASE1
Smartphone Based Smoking Cessation Intervention
NCT03740490 COMPLETED PHASE2/PHASE3
Smoking Cessation Intervention for Cancer Patients
NCT00575718 ACTIVE_NOT_RECRUITING NA